Rowaida Z Taha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/535868/publications.pdf

Version: 2024-02-01

759233 752698 21 791 12 20 citations h-index g-index papers 21 21 21 1160 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Tâ€eell responses and therapies against SARSâ€CoVâ€2 infection. Immunology, 2021, 162, 30-43.	4.4	159
2	DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clinical Epigenetics, 2018, 10, 78.	4.1	103
3	Multiplex epithelium dysfunction due to CLDN10 mutation: the HELIX syndrome. Genetics in Medicine, 2018, 20, 190-201.	2.4	75
4	Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1989-1999.	4.2	75
5	DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clinical Epigenetics, 2018, 10, 104.	4.1	68
6	DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients. Oncolmmunology, 2019, 8, e1542918.	4.6	54
7	Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. Clinical Epigenetics, 2020, 12, 13.	4.1	52
8	PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. Cancers, 2019, 11, 1050.	3.7	50
9	Differential gene expression of tumor-infiltrating CD8 ⁺ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis., 2020, 8, e001294.		25
10	DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF- \hat{l}^2 genes in HLA-DR ^{$\hat{a}\in$"} myeloid cells, compared with HLA-DR ⁺ antigen-presenting cells. Epigenetics, 2020, 15, 1275-1288.	2.7	21
11	Transcriptomic Profiling of Tumor-Infiltrating CD4+TIM-3+ T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients. Vaccines, 2020, 8, 71.	4.4	19
12	Overlap of Familial Mediterranean Fever and Hyper-IgD Syndrome in an Arabic Kindred. Journal of Clinical Immunology, 2015, 35, 249-253.	3.8	15
13	Differential gene expression of tumor-infiltrating CD33+ myeloid cells in advanced- versus early-stage colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 803-815.	4.2	15
14	The M694I/M694I genotype: A genetic risk factor of AA-amyloidosis in a group of Algerian patients with familial Mediterranean fever. European Journal of Medical Genetics, 2017, 60, 149-153.	1.3	14
15	A chromosomal microdeletion of 15q in a female patient with epilepsy, <scp>ID</scp> , and autism spectrum disorder: a case report. Clinical Case Reports (discontinued), 2017, 5, 1013-1017.	0.5	11
16	Epigenetic regulation of immune checkpoints and TÂcell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients. Epigenomics, 2020, 12, 1871-1882.	2.1	11
17	Family-Based Genome-Wide Association Study of Autism Spectrum Disorder in Middle Eastern Families. Genes, 2021, 12, 761.	2.4	7
18	Differential gene expression of tumor-infiltrating CD4 ⁺ T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. Oncolmmunology, 2020, 9, 1825178.	4.6	6

#	Article	IF	CITATIONS
19	Transcriptome of Tumor-Infiltrating T Cells in Colorectal Cancer Patients Uncovered a Unique Gene Signature in CD4+ T Cells Associated with Poor Disease-Specific Survival. Vaccines, 2021, 9, 334.	4.4	5
20	Chronic recurrent multifocal osteomyelitis in a patient with Familial Mediterranean Fever. Pediatric Rheumatology, $2015,13,1$	2.1	4
21	Transcriptomic Profiling of Circulating HLA-DR [–] Myeloid Cells, Compared with HLA-DR ⁺ Myeloid Antigen-presenting Cells. Immunological Investigations, 2021, 50, 952-963.	2.0	2